CoChat

Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias

Open access

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Abstract

Background: Gene mutation is an important mechanism of myeloid leukemogenesis. However, the number and combination of gene mutated in myeloid malignancies is still a matter of investigation. Methods: We searched for mutations in the ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in 65 myelodysplastic syndromes (MDSs) and 64 acute myeloid leukemias (AMLs) without balanced translocation or complex karyotype. Results: Mutations in ASXL1 and CBL were frequent in refractory anemia with excess of blasts. Mutations in TET2 occurred with similar frequency in MDSs and AMLs and associated equally with either ASXL1 or NPM1 mutations. Mutations of RUNX1 were mutually exclusive with TET2 and combined with ASXL1 but not with NPM1. Mutations in FLT3 (mutation and internal tandem duplication), IDH1, IDH2, NPM1 and WT1 occurred primarily in AMLs. Conclusion: Only 14% MDSs but half AMLs had at least two mutations in the genes studied. Based on the observed combinations and exclusions we classified the 12 genes into four classes and propose a highly speculative model that at least a mutation in one of each class is necessary for developing AML with simple or normal karyotype.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1471-2407-10-401

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Examples of mutations in leukemia target genes. a. sequence of CBL demonstrating c.1096G>A base substitution in the forward sequence at the position indicated by an arrow in HD-0264 patient with trisomy 11. The mutation leads to Glu366Lys change in the protein (not tolerated, SIFT). Sequence numbering is according to Genbank accessions numbers NM_005188 and NP_005179. The same sequence from another patient without mutation is shown below for comparison. b. Novel IDH2 mutation in MDS and AML patients. Sequence of IDH2, demonstrating c.419G>A base substitution in the reverse sequence at the position indicated by an arrow in blood cells of patient HD-0104 and its absence in the patient's buccal smear. The mutation leads to Arg140Gln (R140Q) change in the protein (not tolerated, SIFT). Sequence numbering is according to Genbank accessions numbers NM_002168.2 and NP_002159.2.
Figure 1 Examples of mutations in leukemia target genes. a. sequence of CBL demonstrating c.1096G>A base substitution in the forward sequence at the position indicated by an arrow in HD-0264 patient with trisomy 11. The mutation leads to Glu366Lys change in the protein (not tolerated, SIFT). Sequence numbering is according to Genbank accessions numbers NM_005188 and NP_005179. The same sequence from another patient without mutation is shown below for comparison. b. Novel IDH2 mutation in MDS and AML patients. Sequence of IDH2, demonstrating c.419G>A base substitution in the reverse sequence at the position indicated by an arrow in blood cells of patient HD-0104 and its absence in the patient's buccal smear. The mutation leads to Arg140Gln (R140Q) change in the protein (not tolerated, SIFT). Sequence numbering is according to Genbank accessions numbers NM_002168.2 and NP_002159.2.CC BY · PubMed Central
Figure 2 Hypothetical model summarizing frequent gene mutations in the development of two types of acute myeloid leukemia (AML). A hematopoietic stem cell (HSC) or a progenitor cell acquires a series of mutations beginning in class I genes (green). Different additional events (yellow, red and blue) induce clonal expansion and differentiation block and lead either towards secondary AML (sAML) via a patent preleukemic phase or AML without patent preleukemic phase. The order of events may vary.
Figure 2 Hypothetical model summarizing frequent gene mutations in the development of two types of acute myeloid leukemia (AML). A hematopoietic stem cell (HSC) or a progenitor cell acquires a series of mutations beginning in class I genes (green). Different additional events (yellow, red and blue) induce clonal expansion and differentiation block and lead either towards secondary AML (sAML) via a patent preleukemic phase or AML without patent preleukemic phase. The order of events may vary.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 41 references

Cited by

See all 180

Metadata

Authors
Rocquain, J., Carbuccia, N., Trouplin, V., Raynaud, S., Murati, A., Nezri, M., Tadrist, Z., Olschwang, S., Vey, N., Birnbaum, D., Gelsi-Boyer, V., & Mozziconacci, M.-J.
Affiliations
  • Inserm (FR)
  • Aix-Marseille Université (FR)
Venue
BMC Cancer
Published
2010-08-02
Volume
10
Issue
1
Pages
401-401
ISSN
1471-2407 (ISSN-L)
OpenAlex
W2159355068
Cited by
171
References
41
Citations by year
2026: 1 · 2025: 2 · 2024: 2 · 2023: 4 · 2022: 5 · 2021: 12 · 2020: 4 · 2019: 3 · 2018: 6 · 2017: 7 · 2016: 12 · 2015: 13 · 2014: 23 · 2013: 19 · 2012: 30
FWCI
15.41
Type
journal article
Language
en
Open access
Locations
  • BMC Cancer (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • Institut National de la Santé et de la Recherche Médicale
  • Fondation de France
Topics
  • Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Keywords
myelodysplastic syndrome, acute myeloid leukemia, ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2, WT1, refractory anemia with excess blasts, internal tandem duplication
MeSH terms
Nucleophosmin, Aged, Aged, 80 and over, DNA-Binding Proteins, DNA, Neoplasm, Female, Humans, Isocitrate Dehydrogenase, Male, Middle Aged, Mutation, Myelodysplastic Syndromes, Neoplasm Proteins, Nuclear Proteins, Prognosis, Proto-Oncogene Proteins, Genes, ras, Repressor Proteins, Leukemia, Myeloid, Acute, Polymerase Chain Reaction, Proto-Oncogene Proteins p21(ras), ras Proteins, WT1 Proteins, Dioxygenases, Core Binding Factor Alpha 2 Subunit, Proto-Oncogene Proteins c-cbl, fms-Like Tyrosine Kinase 3, Janus Kinase 2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. https://app.cochat.ai/papers/10.1186/1471-2407-10-401
The paper
Rocquain, J., Carbuccia, N., Trouplin, V., Raynaud, S., Murati, A., Nezri, M., Tadrist, Z., Olschwang, S., Vey, N., Birnbaum, D., Gelsi-Boyer, V., & Mozziconacci, M.-J. (2010). Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. BMC Cancer. https://doi.org/10.1186/1471-2407-10-401

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.